Skip to Content

iOS 26.4 Adds Average Bedtime Metric and Restores Blood Oxygen to Health App Vitals Graph

In iOS 26.4, Apple added an Average Bedtime metric to the Sleep section of the Health app, letting users better monitor how bedtime impacts sleep quality.

ios 26 4 average bedtime
Under a new Sleep Highlight, Apple lists the time that you went to bed and the time that you usually go to bed based on averages over a two-week period.

In iOS 26.3, Apple displayed average sleep time over the past seven days. That highlight still exists, but it is now supplemented with the daily bedtime readout.

Apple also updated the Vitals readout in the U.S., and it once again lists blood oxygen level on the line graph overview that's available each day. In iOS 26.3 and earlier versions of iOS 26, there was a section for the blood oxygen level, but the graph did not include a blood oxygen measurement.

ios 26 4 vitals app blood oxygen
Blood oxygen was available as a separate metric in the Vitals section, but it is now visible in the Vitals overview. The Vitals feature did not fully support blood oxygen because of Apple's ongoing legal dispute with Masimo. Masimo accused Apple of infringing on Masimo patents related to blood oxygen sensing, and it secured an import ban from the U.S. International Trade Commission.

Apple had to remove blood oxygen sensing from the Apple Watch starting in early 2024 to be able to continue to sell the Apple Watch in the U.S., but Apple was able to re-add it in August 2025 with blood oxygen readouts available only on the iPhone. There is still no option to measure blood oxygen with the Apple Watch and see the results directly on the wrist in the U.S.

iOS 26.4 is available to developers and public beta testers, with a public launch planned for spring.

Related Roundups: iOS 26, iPadOS 26
Related Forum: iOS 26

Popular Stories

macbook air blue

What's Coming in the M5 MacBook Air

Thursday February 26, 2026 3:57 pm PST by
Along with the low-cost MacBook, Apple could introduce a refreshed version of the MacBook Air next week. Most of the focus will be on the new machine, but the MacBook Air is expected to get some useful internal updates. M5 Chip The next-generation MacBook Air will adopt the M5 chip, which Apple already introduced in the iPad Pro and MacBook Pro models that came out last year. Apple's M5...
ipad mini 7 1

Could Apple's OLED iPad Mini Finally Be a Kindle Killer?

Friday February 27, 2026 12:08 pm PST by
With a similar screen size and easy, one-handed grip, the iPad mini has always been the Apple device that overlaps most with dedicated e-readers. Now, amid rumors pointing to an OLED display for the next generation, could the iPad mini finally replace devices such as the Kindle and Kobo? The shift from LCD to OLED could make the iPad mini far more appealing as a reading device. OLED panels...
Apple Announces Special Event in New York Feature 1

Apple Teases 'A Big Week Ahead' With Announcements Starting Monday

Thursday February 26, 2026 6:06 am PST by
Apple CEO Tim Cook today teased "a big week ahead," with announcements starting Monday. His post included an #AppleLaunch hashtag with a colorful Apple logo, along with a short video that ultimately shows an Apple logo on the lid of a Mac. Apple is reportedly planning a three-day stretch of product announcements from Monday, March 2 through Wednesday, March 4, with up to five new products...

Top Rated Comments

2 weeks ago
I think the author of this article needs to sleep earlier!
Score: 4 Votes (Like | Disagree)
jz0309 Avatar
2 weeks ago

It should be noted that Masimo is being bought by Danaher. Danaher will have deeper pockets to fight back against Apple.

https://www.reuters.com/business/healthcare-pharmaceuticals/danaher-buy-masimo-99-billion-2026-02-17/

Feb 17 (Reuters) - Danaher will acquire Masimo in a $9.9 billion deal, as it looks to expand its diagnostics portfolio with the California-based medtech company's devices to monitor blood oxygen levels.

The companies said on Tuesday that Danaher will pay $180 per share to buy Masimo. The offer represents 38.3% premium to Masimo's last close.

The deal marks a rare move beyond life sciences company Danaher's core drug-development tools business, to gain a foothold in the market for blood oxygen monitoring products, a segment dominated by Medtronic and Masimo.

The deal with Masimo broadens Danaher's diagnostic segment, complementing its invasive Radiometer blood analyzer devices with Masimo's non-invasive pulse oximeters, brain function and respiration monitoring devices, among other products.

while the pockets might be deeper, they might also be smarter in not spending money on lawyers with the remaining life of those patents quite limiting ...
Score: 4 Votes (Like | Disagree)
2 weeks ago

while the pockets might be deeper, they might also be smarter in not spending money on lawyers with the remaining life of those patents quite limiting ...
Not to mention that the patent in contention expired in 2022. It's not clear why Apple has not fully re-enabled O2 in the US by now, but it doesn't appear that there is any legal reason for Apple to continue using the workaround.

My guess is that they are simply waiting until the ongoing litigation comes to an end. So if the new owners aren't going to continue pursuing Apple in court or are more willing to settle with Apple, this entire saga may finally come to an end and consumers in the US may finally get back full O2 functionality on Apple Watch.
Score: 4 Votes (Like | Disagree)
jz0309 Avatar
2 weeks ago
Getting the blood oxygen back into the vitals view will be very nice
Score: 4 Votes (Like | Disagree)
sw1tcher Avatar
2 weeks ago

Not to mention that the patent in contention expired in 2022. It's not clear why Apple has not fully re-enabled O2 in the US by now, but it doesn't appear that there is any legal reason for Apple to continue using the workaround.
The patents expire in August 2028.

https://patents.google.com/patent/US10912502B2/en

https://patents.google.com/patent/US10945648B2/en

https://news.bloomberglaw.com/ip-law/masimo-sues-us-customs-over-apple-restoring-watchs-oxygen-tool

US Customs and Border Protection unlawfully let Apple Inc. reactivate a blood-oxygen tracking feature on Apple Watches that infringes patents for the technology, Masimo Corp. said in a federal lawsuit.

CBP exceeded its authority in an Aug. 1 internal advice ruling that overturned its own January decision without notice or input from Masimo, the medical-device maker said in a complaint filed Wednesday in the US District Court for the District of Columbia. Masimo brought claims under the Administrative Procedure Act and the Fifth Amendment’s due process clause.

Apple announced Aug. 14 that software updates would restore the blood-oxygen feature for US Apple Watch owners by shifting calculations to paired iPhones rather than the watch itself. Masimo said that was the first time it learned CBP had quietly reversed course two weeks earlier in an ex parte ruling, despite the agency’s policy that such decisions normally require both sides to be heard. The feature has been banned on US Apple Watches since the US International Trade Commission in October 2023 found it infringes claims in two Masimo patents.


[ . . . ]

Masimo said the reversal “effectively nullified” an October 2023 limited exclusion order from the ITC, which found Apple Watches infringe US Patent Nos. 10,912,502 and 10,945,648 covering non-invasive pulse oximetry. Apple’s appeal of the ban is pending at the Federal Circuit.
Score: 2 Votes (Like | Disagree)
2 weeks ago
Good to see these changes. However I don't use these health features much and so not much benefit.
Score: 1 Votes (Like | Disagree)
Related Apple News: South Africa | Lifestyle | Education | Reviews | Entertainment